Marzo, Manuela
 Distribuzione geografica
Continente #
EU - Europa 929
NA - Nord America 860
AS - Asia 257
AF - Africa 2
OC - Oceania 1
Totale 2.049
Nazione #
US - Stati Uniti d'America 854
DE - Germania 447
SE - Svezia 126
CN - Cina 114
UA - Ucraina 89
IT - Italia 73
SG - Singapore 67
FR - Francia 55
GB - Regno Unito 48
IE - Irlanda 34
IN - India 31
FI - Finlandia 24
ID - Indonesia 19
TR - Turchia 14
BE - Belgio 10
RU - Federazione Russa 9
IR - Iran 7
CA - Canada 6
JP - Giappone 3
PL - Polonia 3
CH - Svizzera 2
CI - Costa d'Avorio 2
GR - Grecia 2
NL - Olanda 2
TW - Taiwan 2
AU - Australia 1
BG - Bulgaria 1
EE - Estonia 1
HU - Ungheria 1
ME - Montenegro 1
RO - Romania 1
Totale 2.049
Città #
Chandler 202
Jacksonville 78
Ashburn 62
Dearborn 54
Singapore 52
Ann Arbor 49
San Mateo 42
New York 40
Cattolica 34
Dublin 33
Nürnberg 26
Nanjing 24
Wilmington 22
Munich 21
Bremen 19
Jakarta 19
Beijing 18
Milan 16
Lawrence 15
Izmir 13
Houston 12
Lancaster 11
Brussels 10
Boston 9
Los Angeles 9
Jiaxing 7
Leawood 7
Moscow 7
Nanchang 7
Seattle 7
Shenyang 7
Woodbridge 7
Ardabil 6
Fairfield 6
Helsinki 6
Boardman 5
Mountain View 5
Marseille 4
Princeton 4
Redwood City 4
Shanghai 4
Augusta 3
Changsha 3
Costa Mesa 3
Detroit 3
Edinburgh 3
Hangzhou 3
Hebei 3
Hefei 3
Kraków 3
Millbury 3
Rome 3
Tianjin 3
Toronto 3
University Park 3
Abidjan 2
Andover 2
Changchun 2
Fremont 2
Guangzhou 2
Jinan 2
Lanzhou 2
London 2
Napoli 2
Norwalk 2
Pune 2
Taipei 2
Ahmedabad 1
Amsterdam 1
Athens 1
Bern 1
Budapest 1
Canberra 1
Clearwater 1
Delhi 1
Easton 1
Frankfurt am Main 1
Fuzhou 1
Indiana 1
Ipswich 1
Kish 1
Kunming 1
Kyiv 1
Ladispoli 1
Landshut 1
Moncalieri 1
Monmouth Junction 1
Montreal 1
Montréal 1
Ningbo 1
Novara 1
Ocean Grove 1
Ottawa 1
Pittsburgh 1
Podgorica 1
Quzhou 1
Raritan 1
Ribera 1
Sacramento 1
San Jose 1
Totale 1.082
Nome #
FOXP3⁺ T regulatory cell modifications in inflammatory bowel disease patients treated with anti-TNFα agents 153
Comparison of Quantiferon-TB Gold versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease patients. 144
Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study 144
Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open-label pilot study 139
Immune response to influenza A/H1N1 vaccine in inflammatory bowel disease patients treated with anti TNF-α agents: Effects of combined therapy with immunosuppressants. 135
Infliximab in Steroid-dependent Ulcerative Colitis: Effectiveness and Predictors of Clinical and Endoscopic Remission. 135
Development of psoriasis scalp with alopecia during treatment of Crohn's disease with infliximab and rapid response to both diseases to ustekinumab 123
Achievement of sustained deep remission with adalimumab in a patient with both refractory ulcerative colitis and seronegative erosive rheumatoid arthritis 120
Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor-α agents 114
Dermatological adverse reactions during anti-TNF treatments: Focus on inflammatory bowel disease. 106
Ileal Crohn's disease: CEUS determination of activity 105
Ileal Crohn disease: mural microvascularity quantified with contrast-enhanced US correlates with disease activity 99
Ileal Crohn disease: mural microvascularity quantified with contrast-enhanced US correlates with disease activity 94
Prevention and treatment of venous thromboembolism in patients with IBD: a trail still climbing. 89
Therapeutic drug monitoring of anti-TNF-α agents in inflammatory bowel diseases 87
What is the best way to manage screening for infections and vaccination of inflammatory bowel disease patients? 77
Management of perianal fistulas in Crohn's disease: an up-to-date review 76
Therapeutic drug monitoring is more cost-effective than a clinically-based approach in the management of loss of response to infliximab in inflammatory bowel disease: an observational multi-centre study. 71
Acute cytomegalovirus infection as a possible trigger for pulmonary thromboembolism in a patient with steroid-refractory ulcerative colitis. 50
Totale 2.061
Categoria #
all - tutte 6.840
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 6.840


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020215 0 0 0 0 28 57 26 13 26 9 33 23
2020/2021167 4 19 3 22 22 3 13 9 24 2 41 5
2021/2022218 31 18 4 39 7 2 3 39 4 3 30 38
2022/2023462 61 64 21 100 33 54 16 36 61 2 8 6
2023/2024187 10 46 2 16 2 42 3 25 2 5 15 19
2024/202598 5 21 35 6 31 0 0 0 0 0 0 0
Totale 2.061